IL6 and episodic ataxia type 2: Finally, although not yet approved for the treatment of patients with severe COVID-19 in alternative to anti-IL-6 agents, future research could assess the potential role of monoclonal antibodies targeting IL-1 (anakinra and canakinumab) in patients with cytokine storm and high risk of CAPA.